Avanos Medical Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect eight nominees (Gary D. Blackford; William P. Burke; James L. Cunniff; Dr. Lisa Egbuonu-Davis; Indrani L. Franchini; Patrick J. O’Leary; David C. Pacitti; Dr. Julie Shimer) to serve one-year terms until 2027 Annual Meeting.

2. 2

   Ratification of Appointment of Auditors

   ManagementBoard: FOR

   Ratify appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026.

3. 3

   Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding advisory vote to approve the compensation paid to the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   This proposal asks shareholders for a non-binding advisory approval of the compensation paid to the Company’s named executive officers as disclosed in the proxy. Management seeks endorsement of its 2025 compensation design — a mix of base salary, annual cash incentives tied to adjusted net sales, adjusted EBITDA and strategic initiatives, and long-term equity awards (50% PRSUs, 25% TRSUs, 25% options) — arguing that prior investor engagement and consultant advice resulted in a pay-for-performance structure aligned to stockholder interests. The Compensation Committee emphasizes multi-year performance metrics, clawback provisions, stock ownership guidelines and caps on incentives to mitigate excessive risk. A vote FOR supports management’s approach and signals shareholder acceptance of the program; a vote AGAINST or significant opposition would ordinarily trigger further engagement and potential plan revisions. Contextually, the company returned to options in 2025 to reinforce alignment and used free cash flow and ROIC in PRSUs; 2025 actual results produced above-target payouts on several measures, informing the Committee’s view that the program is functioning. The recommendation is FOR because the Board believes the program appropriately balances retention, pay-for-performance and alignment with long-term value creation, while retaining governance safeguards such as an independent compensation consultant, policies limiting repricing and clawbacks. The proposal is advisory and not binding, but the Board and Compensation Committee will consider voting results in future program design.

4. 4

   Amendment of 2021 Long Term Incentive Plan to allow outside directors to receive awards

   ManagementBoard: FOR

   Approve an amendment to the 2021 Long Term Incentive Plan to permit issuance of awards under the plan to outside (non-employee) directors; amendment does not increase share reserve and will not cause dilution.

   More detail

   This management proposal requests shareholder approval to amend the Company’s existing 2021 Long Term Incentive Plan so that outside (non-employee) directors are eligible to receive equity awards under the 2021 Plan. Management explains the operational rationale: the separate Outside Directors’ Compensation Plan has only ~14,181 shares remaining, insufficient for normal 2026 grants; rather than increase the older plan’s share reserve, the Company proposes to use the existing 2021 Plan’s share pool (4.5 million shares authorized) without increasing the overall reserve, thereby avoiding additional dilution. The amendment would not change award terms, vesting, or governance; rather, it only expands eligible participants to include outside directors. The Board unanimously recommends FOR, noting continuity of director cash compensation and equivalence of award terms. For governance analysts, key considerations include that the change centralizes equity grants into the main incentive plan — potentially improving administrative efficiency — but could reduce transparency if director awards are less clearly segregated; however, the Company confirms no incremental share reserve expansion and that terms remain consistent (e.g., RSUs settling after retirement or service termination, minimum vesting rules, and shareholder protections such as anti-repricing and adjustment provisions). The proposal appears targeted and limited in scope: it addresses a logistical need while preserving shareholder dilution protections and existing plan governance safeguards (Committee administration, potential clawback policy application, and minimum vesting exceptions). Analysts should note the Board’s stated intent to continue paying cash components under the Outside Director Compensation Plan and to make the 2026 annual director equity grants under the 2021 Plan only if the amendment is approved. Overall, the proposal is a narrowly scoped governance housekeeping measure, favorable from a dilution and oversight perspective, but investors may scrutinize future director award levels, grant timing changes, and whether this centralization materially affects director compensation benchmarking or oversight.

Upcoming shareholder meetings at Avanos Medical Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Avanos Medical Inc 2026 annual meeting?

Avanos Medical Inc (AVNS) holds its 2026 annual shareholder meeting on Tuesday, April 21, 2026.

What is the record date for the Avanos Medical Inc 2026 meeting?

The record date for the Avanos Medical Inc 2026 meeting is Friday, February 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Avanos Medical Inc's 2026 meeting?

The board is presenting 8 director nominees at the Avanos Medical Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Avanos Medical Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Avanos Medical Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.